OM
SAGE

Opaleye Management’s Sage Therapeutics SAGE Stock Holding History

Opaleye Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-45,000
Closed -$3.2M – 48
2017
Q1 		$3.2M Buy
45,000
+10,000
+29% +$586K 1.59% 20
2016
Q4 		$1.79M Buy
+35,000
New +$1.65M 1.05% 30
2016
Q2 		– Sell
-165,000
Closed -$5.29M – 55
2016
Q1 		$5.29M Buy
165,000
+65,000
+65% +$2.29M 3.3% 9
2015
Q4 		$5.83M Buy
100,000
+80,000
+400% +$3.96M 2.44% 18
2015
Q3 		$846K Buy
+20,000
New +$1.23M 0.42% 42

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Opaleye Management's SAGE Position: Q2 2017 in Review

Opaleye Management sold out of Sage Therapeutics (SAGE) in Q2 2017, closing a stake of 45,000 shares — an estimated $3.2M sold.

Opaleye Management first reported a position in SAGE in Q3 2015 and held it in 5 quarters. The position peaked at $5.83M in Q4 2015. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2017.

  • Opaleye Management reported no remaining Sage Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Opaleye Management sold 45,000 Sage Therapeutics shares in Q2 2017, an estimated $3.2M.
  • Opaleye Management first reported a position in Sage Therapeutics in Q3 2015 and held it in 5 quarters.
  • Opaleye Management's Sage Therapeutics position peaked at $5.83M in Q4 2015.
  • 191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2017.

Based on Opaleye Management's 13F filing for Q2 2017, filed 14 Aug 2017.